Literature DB >> 24355429

Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery.

Thomas Ebert1, Holger Stepan2, Susanne Schrey2, Susan Kralisch3, Janka Hindricks3, Lisa Hopf3, Martin Platz3, Ulrike Lossner3, Beate Jessnitzer4, Sascha Drewlo5, Matthias Blüher4, Michael Stumvoll4, Mathias Fasshauer3.   

Abstract

OBJECTIVE: Irisin has recently been introduced as a novel an exercise-inducible myokine which improves glucose metabolism in mice. However, regulation of circulating irisin in gestational diabetes mellitus (GDM) and in the peripartal period has not been assessed so far.
METHODS: Circulating irisin was quantified in 74 GDM patients and in 74 healthy, pregnant, gestational age-matched controls. In a subset of these patients (44 GDM, 41 controls), postpartum follow-up data were also available. In a second study population of 40 healthy women with singleton pregnancies undergoing elective Cesarean section, irisin was assessed in maternal serum before and within 24h after delivery, as well as in umbilical cord blood and in placental tissue.
RESULTS: In the first study population, median [interquartile range] irisin levels were significantly higher in GDM patients as compared to controls after delivery (previous GDM: 446.3 [146.9]μg/l; controls: 378.0 [111.4]μg/l) but not during pregnancy (GDM: 482.1 [132.1]μg/l; controls: 466.6 [178.0]μg/l). Interestingly, fasting insulin (FI) was independently and positively associated with serum irisin in multivariate analysis during pregnancy. In agreement with these findings, relative changes (ratio) of FI independently and positively predicted relative changes of irisin (ratio) in the second study population.
CONCLUSIONS: The myokine irisin is independently associated with FI in pregnancy. The physiological significance of these findings needs to be assessed in future experiments.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AFABP; BMI; C reactive protein; CRP; ELISA; FFA; FG; FGF-21; FI; GDM; Gestational diabetes mellitus; HDL; HOMA-IR; HbA1c; Irisin; LDL; Myokine; OGTT; Pregnancy; T2DM; TG; WHR; adipocyte fatty acid-binding protein; body mass-index; enzyme-linked immunosorbent assay; fasting glucose; fasting insulin; fibroblast growth factor-21; free fatty acids; gestational diabetes mellitus; glycosylated hemoglobin A1c; high density lipoprotein; homeostasis model assessment of insulin resistance; low density lipoprotein; oral glucose tolerance test; triglycerides; type 2 diabetes mellitus; waist to hip-ratio

Mesh:

Substances:

Year:  2013        PMID: 24355429     DOI: 10.1016/j.cyto.2013.11.009

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  25 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  Comprehensive evaluation of irisin levels in fetomaternal circulation of pregnant women with obesity or gestational diabetes mellitus.

Authors:  Ali Seven; Esin Yalinbas; Suna Kabil Kucur; Emel Kocak; Ozben Isiklar; Beril Yuksel; Hakan Timur; Mehmet Erbakirci; Nadi Keskin
Journal:  Ir J Med Sci       Date:  2019-05-17       Impact factor: 1.568

3.  Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?

Authors:  Beatriz García-Fontana; Rebeca Reyes-García; Sonia Morales-Santana; Verónica Ávila-Rubio; Araceli Muñoz-Garach; Pedro Rozas-Moreno; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2015-10-05       Impact factor: 3.633

4.  Irisin in idiopathic foetal growth restriction.

Authors:  Mete Çağlar; Mehmet Göksu; Bekir Sıtkı Isenlik; Ali Yavuzcan; Musa Yılmaz; Yusuf Üstün; Suleyman Aydin; Selahattin Kumru
Journal:  J Endocrinol Invest       Date:  2014-05-01       Impact factor: 4.256

5.  Analysis of Changes in Serum Levels and Gene Expression Profiles of Novel Adipocytokines (Omentin, Vaspin, Irisin and Visfatin) and Their Correlation with Serum C-reactive Protein Levels in Women Diagnosed with Endometriosis

Authors:  Ecem Kaya Sezginer; Ömer Faruk Kırlangıç; Merve Didem Eşkin Tanrıverdi; Hasan Onur Topçu; Serap Gür
Journal:  Turk J Pharm Sci       Date:  2022-02-28

Review 6.  Prenatal exercise in fetal development: a placental perspective.

Authors:  Song Ah Chae; Jun Seok Son; Min Du
Journal:  FEBS J       Date:  2021-09-12       Impact factor: 5.622

7.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

8.  Association of metabolic parameters and rs726344 in FNDC5 with serum irisin concentrations.

Authors:  T Ebert; S Kralisch; U Wurst; M Scholz; M Stumvoll; P Kovacs; M Fasshauer; A Tönjes
Journal:  Int J Obes (Lond)       Date:  2015-08-19       Impact factor: 5.095

9.  Cord blood irisin levels are positively correlated with birth weight in newborn infants.

Authors:  Kyoung Eun Joung; Kyung-Hee Park; Andreas Filippaios; Fadime Dincer; Helen Christou; Christos S Mantzoros
Journal:  Metabolism       Date:  2015-07-29       Impact factor: 8.694

10.  SERUM IRISIN LEVEL INCREASES THROUGHOUT THE GESTATIONAL PERIOD AND IT DOES NOT PLAY A ROLE IN DEVELOPMENT OF GESTATIONAL DIABETES MELLITUS.

Authors:  S Sancak; H Aydın; M Sargin; A Orçun; A Özdemir; A Çelik; B Sunar; G Aslan
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.